Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 8/20 | 0.53 |
| ▸ | GRIN3B | O60391 | 8/20 | 0.53 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 8/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 8/20 | 0.53 |
| ▸ | GRIN3A | Q8TCU5 | 8/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1303787 | 0.85 | ABCG2 (0.51) | MEN1KMT2AALDH1A1NPC1RAB9A | |
| SCHEMBL1135824 | 0.79 | GRIN2D (0.49) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1135619 | 0.78 | GRIN2D (0.41) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2419187 | 0.75 | GRIN2D (0.54) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1135596 | 0.75 | ELANE (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL21676336 | 0.74 | GRIN2D (0.50) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL27489183 | 0.74 | GRIN2D (0.40) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1135620 | 0.74 | KDM4E (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1135811 | 0.74 | GRIN2D (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL13982717 | 0.72 | ABCG2 (0.67) | MEN1KMT2AALDH1A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011524384-A | — | — | 2011-09-01 | — | — | JP | claimed |
| US-20110130404-A1 | QUINOXALINEDIONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-06-02 | — | — | US | claimed |
| EP-2285786-A1 | QUINOXALINEDIONE DERIVATIVES | Merck Patent GmbH (DE) | 2011-02-23 | — | — | EP | claimed |
| WO-2009152909-A1 | QUINOXALINEDIONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-23 | — | — | WO | claimed |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | DONG WHA PHARM. CO., LTD. (KR) | 2021-06-08 | — | — | US | disclosed |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | DONG WHA PHARM. CO., LTD. (KR) | 2021-06-08 | — | — | US | disclosed |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-02-06 | — | — | US | disclosed |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2020-02-06 | — | — | US | disclosed |
| US-8674097-B2 | Quinoxalinedione derivatives useful as activators of AMPK-activated protein kinase | MERCK PATENT GMBH (DE) | 2014-03-18 | — | — | US | disclosed |
| US-20120322806-A1 | QUINOXALINEDIONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-12-20 | — | — | US | disclosed |
| US-8329698-B2 | Quinoxalinedione derivatives which are activators of AMPK-activated protein kinase | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-12-11 | — | — | US | disclosed |
| US-20110130404-A1 | QUINOXALINEDIONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-06-02 | — | — | US | disclosed |
| EP-2285786-A1 | QUINOXALINEDIONE DERIVATIVES | Merck Patent GmbH (DE) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009152909-A1 | QUINOXALINEDIONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-12-23 | — | — | WO | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1720868-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005077944-A1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130404-A1 | QUINOXALINEDIONE DERIVATIVES | GLP1R, GPR119, NDUFS3 | GRIN2D 2417/4885GRIN3B 3796/4885GRIN1 2215/4885 |
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | GRIN2D 711/4885GRIN3B 546/4885GRIN1 555/4885 |
| US-11028090-B2 | [1,2,4]Triazolo[4,3-a]quinoxaline derivative, method for preparing same, and pharmaceutical composition for preventing or treating BET protein-related diseases, containing same as active ingredient | BRD4, BET1, BRD3 | GRIN2D 4382/4885GRIN3B 3751/4885GRIN1 2316/4885 |
| US-20200039984-A1 | Novel [1,2,4]Triazolo[4,3-a]Quinoxaline Derivative, Method For Preparing Same, And Pharmaceutical Composition For Preventing Or Treating BET Protein-Related Diseases, Containing Same As Active Ingredient | BRD4, BET1, BRD3 | GRIN2D 4401/4885GRIN3B 3824/4885GRIN1 2352/4885 |
| US-20120322806-A1 | QUINOXALINEDIONE DERIVATIVES | GLP1R, GPR119, NDUFS3 | GRIN2D 2417/4885GRIN3B 3796/4885GRIN1 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.